Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126948931 | 12694893 | 1 | I | 201607 | 20160823 | 20160829 | 20160829 | EXP | US-MYLANLABS-2016M1035776 | MYLAN | 0.00 | Y | 0.00000 | 20160829 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126948931 | 12694893 | 1 | PS | LETROZOLE. | LETROZOLE | 1 | UNK | 78190 | |||||||||||
126948931 | 12694893 | 2 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | 125 MG, QD | Y | U | 0 | 125 | MG | CAPSULE | QD | ||||
126948931 | 12694893 | 3 | SS | FASLODEX | FULVESTRANT | 1 | UNK | Y | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126948931 | 12694893 | 1 | Breast cancer metastatic |
126948931 | 12694893 | 2 | Breast cancer metastatic |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126948931 | 12694893 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126948931 | 12694893 | Feeling abnormal | |
126948931 | 12694893 | Hypoaesthesia | |
126948931 | 12694893 | Peripheral swelling |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126948931 | 12694893 | 1 | 20160722 | 0 | ||
126948931 | 12694893 | 2 | 2016 | 0 | ||
126948931 | 12694893 | 3 | 20160721 | 20160721 | 0 |